Healthcare Equipment and Supplies
Company Overview of Silk Road Medical, Inc.
Silk Road Medical, Inc. develops and manufactures less-invasive medical devices to improve treatment of carotid artery diseases through proprietary transcarotid therapies. The company was founded in 2007 and is based in Sunnyvale, California.
735 North Pastoria Avenue
Sunnyvale, CA 94085
Founded in 2007
Key Executives for Silk Road Medical, Inc.
Chief Executive Officer, President and Director
Vice President of Finance & Administration
Senior Vice President of Operations
Compensation as of Fiscal Year 2015.
Silk Road Medical, Inc. Key Developments
Silk Road Medical, Inc. Announces CE Mark Approval for its Next Generation ENROUTE Transcarotid Neuroprotection System
Mar 15 16
Silk Road Medical, Inc. announced CE Mark approval for its next generation ENROUTE Transcarotid Neuroprotection System (NPS). The ENROUTE NPS remains the only device specifically designed and indicated for TransCarotid Artery Revascularization (TCAR), a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. In partnership with treating physicians and based on feedback from over 700 TCAR procedures, the ENROUTE NPS was enhanced and upgraded to provide physicians with an even more dependable and easy-to-use system to treat their patients in the safest manner possible. The ENROUTE NPS allows the physician to directly access the common carotid artery in the neck and initiate high rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting Silk Road's ENROUTE® Transcarotid Stent. The first TCAR procedures with the new ENROUTE NPS were recently performed in European hospitals including the Virgen de la Salud Hospital in Toledo, Spain, Klinikum rechts der Isar (Technische Universität München) in Munich, Germany, Augusta Krankenhaus in Dusseldorf Germany, John Paull II Hospital in Krakow, Poland and Gent University Hospital in Gent, Belgium.
Silk Road Medical Announces First U.S. Commercial Case with the ENROUTE Transcarotid Stent System
Oct 6 15
Silk Road Medical Inc. announced the first U.S. commercial case using the ENROUTE Transcarotid Stent System was successfully performed at Kaiser Permanente Moanalua Medical Center in Honolulu, HI, by Vascular Surgeon Peter A. Schneider, M.D. The ENROUTE Transcarotid Stent is the first and only carotid stent designed specifically for a new procedure called TransCarotid Artery Revascularization, or TCAR. TCAR combines surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE Transcarotid Stent is indicated for use in High Surgical Risk patients and is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure. The ENROUTE Transcarotid NPS is a first in class device used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent. The ENROUTE Transcarotid Stent was granted Premarket Approval (PMA) from the United States Food & Drug Administration (FDA) in May of 2015 based in part on data collected from a subset (52) of 141 High Surgical Risk patients in the ROADSTER study who were treated with the Cordis PRECISE PRO RX® Stent System and the ENROUTE Transcarotid NPS. The ENROUTE Transcarotid Stent was developed pursuant to a license with Cordis Corporation and leverages the micromesh design and long term durability of the Cordis Precise® Carotid Stent that was clinically proven in tens of thousands of patients across multiple clinical trials including SAPPHIRE, CASES-PMS and SAPPHIRE Worldwide.
Silk Road Medical Appoints Andrew Davis as Executive Vice President of Global Sales
May 28 15
Silk Road Medical Inc. announced the appointment of Andrew (Andy) Davis to the position of Executive Vice President of Global Sales. In this new role, Andy will assemble a sales organization and lead the company's commercialization efforts for the TransCarotid Artery Revascularization (TCAR) procedure with the ENROUTE® Transcarotid Neuroprotection System (NPS) and the ENROUTE® Transcarotid Stent System. Prior to joining Silk Road Medical, Andy was the Vice President of Sales and Marketing at Acelity's Advanced Wound Therapy Group and previously held Vice President of Sales positions for Medtronic's CoreValve, Endovascular, Peripheral and Spinal/Biologics divisions.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 13, 2015
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries